Wednesday, June 3, 2020

Lupin inks distribution pact with 3 firms to commercialise NaMuscla in Europe

Lupin inks distribution pact with 3 firms to commercialise NaMuscla in Europe Exeltis Healthcare SL, Cresco Pharma BV and Macure Pharma ApS will commercialise NaMuscla for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in certain European Union (EU) territories, Lupin said in a statement.

from Moneycontrol Business News https://ift.tt/3eCIAUW
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Nifty eyes relief rally on tariff hopes, FIIs remain a drag

Markets anticipate a rebound early in the shortened week following news of potential tariff removal on India. Despite oversold conditions, a...